MyClimb Study: 93% Pediatric MYBPC3-HCM Is Nonobstructive
Test Summary: MYBPC3 Genetic Testing
- Sample Required: Blood or saliva
- Fasting Rules: Not required
- Turnaround Time: 2-3 weeks
- Base Cost: [Insert Current 2026 Price]
Tenaya's interim MyClimb data suggest 93% of children with MYBPC3-associated HCM have the nonobstructive form with no approved therapies today, highlighting an urgent need for disease-modifying options and better risk stratification.
Key Findings from the MyClimb Study
- The MyClimb natural history study analyzed 213 pediatric MYBPC3-HCM cases from 27 centers across the U.S., Canada, Spain, and the U.K., making it the largest study of its kind in children to date.
- Presented at ESC 2025, the interim readout shows most pediatric cases are nonobstructive, a phenotype lacking approved treatment pathways and often progressing rapidly.
Genetic Basis and Phenotypic Variability
Three inheritance patterns map to distinct clinical risks. Homozygous (biallelic truncating variants) present the most severe, early course with transplant or death before age one in nearly all cases. Compound heterozygous (one truncating + one missense variant) show early diagnosis and high heart failure hospitalization and transplant/death rates. Heterozygous cases fare better but still carry substantial morbidity.
| Genotype | Clinical Course | Key Risks |
|---|---|---|
| Homozygous (biallelic truncating) | Most severe, early onset | Transplant or death before age 1 |
| Compound heterozygous | Early diagnosis, rapid progression | High HF hospitalization, transplant/death |
| Heterozygous | Better prognosis but still significant | Substantial morbidity, arrhythmias |
Genotype-based profiling can inform counseling, surveillance intensity, and future trial stratification to tailor emerging therapies.
LVMI as a Prognostic Biomarker
Left Ventricular Mass Index (LVMI) emerged as a predictor of adverse events: each 10 g/m² increase was associated with about a 10% higher hazard of serious outcomes in compound heterozygous and heterozygous groups.
Investigators propose LVMI as a practical surrogate endpoint to gauge early efficacy in pediatric gene therapy trials targeting MYBPC3.
Current Clinical Gaps in Pediatric Management
With 93% nonobstructive HCM and no approved therapies, current pediatric management leans on invasive interventions (ICDs, transplant) that do not address root causes and carry complication risks—underscoring unmet need.
The study reinforces the importance of genetic diagnosis, family counseling, and close monitoring to anticipate arrhythmias, HF hospitalizations, and transplant needs.
Emerging Therapies: TN-201 Gene Therapy
Tenaya's AAV9 gene therapy TN-201 delivers a functional MYBPC3 via single IV infusion; early-phase data showed initial patients improving to NYHA Class I, with more cohort data expected in Q4 2025.
Regulatory momentum includes U.S. Fast Track, Orphan Drug, Rare Pediatric Disease designations and EU orphan designation, enabling accelerated development if efficacy signals persist.
Why Genetic Testing Matters
At DNA Labs India, we offer comprehensive genetic testing for cardiomyopathy, including MYBPC3 gene sequencing using Next-Generation Sequencing (NGS). Our ISO 9001 certified lab ensures accurate and reliable results. Early genetic diagnosis enables proactive management and family screening.
Frequently Asked Questions
What makes pediatric MYBPC3-HCM different?
Earlier onset, faster progression, and higher risk tied to genotype compared with many adult cases, necessitating pediatric-specific data and endpoints.
Why is nonobstructive HCM so challenging?
Lack of obstruction-focused drug targets leaves few options; disease-modifying strategies must address sarcomeric deficiency and remodeling.
How could LVMI help trials?
As a quantifiable, prognostic marker, LVMI can shorten study timelines by reflecting early structural change before hard outcomes accrue.
Is gene therapy realistic for kids?
Early signals are encouraging; durability, dosing, and safety will drive viability, with regulatory designations supporting pathway acceleration.